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LETTERS TO THE EDITORChallenges in Hematopoietic
Stem Cell TransplantationThe article by Gajewski et al. [1] regarding
projected shortages in physicians specialized in hema-
topoietic stem cell transplantation (HSCT) deals
with issues of capital importance for the delivery of
state-of-the-art medical care. The scope of HSCT
keeps expanding, and will include a number of nonma-
lignant/nonhematologic disorders, as diverse (and yet
as similar) as systemic lupus erythematosus and
Crohn’s disease. At the same time, the needs for tradi-
tional indications, such as thalassemia, are not being
met. In the United States alone, up to 70,000 patients
with sickle cell disease—only 1 of the current indica-
tions—could benefit from nonmyeloablative HSCT
[2]. The current rate of 18,000 procedures/year men-
tioned by the authors would prove a gross underesti-
mate were HSCT to reach its full dimensions. Now,
the anticipated undersupply of trained transplant spe-
cialists is expected to further aggravate the problem.
Interestingly, this supply crisis comes at a time of
amazing developments in the science of regenerative
medicine, which, through cell reprogramming, not
only promises to make HSCT as we know it today ob-
solete, but puts the therapeutic modalities of the whole
specialty of hematology-oncology under a different
perspective. Unfortunately, although science always
finds a way to reset the standards of medicine, medi-
cine has yet to find a simple way to absorb science.
In a similar situation, the unprecedented growth of
knowledge in molecular biology in the last 20 years
determined the course of many an academic career
but had a negligible impact on the early career choices
of young physicians. In fact, the huge potential of such
a wealth of knowledge was exploited, but too little, in
the clinical practice of medicine. The shortcomings,
however, of medicine have never stopped market
forces from exerting their power or industries from
taking advantage of scientific breakthroughs. In the
case of molecular biology, the proverbial delay of
clinicians to catch up with scientific progress led to
the institution of a whole kind of medicine, the
personalized medicine, which grows over and above
the heads of the medical community. If hematology-
oncology is not immune to similar manipulations, it
could appear that not only the train of HSCT is about
to be missed for lack of manpower, funds, and range,
but the next 1, of regenerative medicine, may be missed
too—and for the same reasons.560It is surprising that the authors halted their presen-
tation just a moment before voicing the obvious solu-
tion: a structured HSCT fellowship followed by board
certification—as it has already been recently proposed
[3]. Furthermore though, the HSCT workforce may
have to be redefined. That more hematologists-
oncologists will be attracted by such a fellowship needs
not be discussed: if it were to happen, it would have al-
ready happened. An HSCT fellowship, however, could
enroll fellowship-trained, board-certified physicians
from the other 2 specialties who have a relevant back-
ground, legitimate interest in HSCT, and practice
that will benefit from it: allergy-immunology and
rheumatology. What HSCT stands to gain from such
an expansion of its recruitment basis is its graduation
to a whole different scale in terms of numbers, function
and, eventually, political weight. At this time a number
of Allergists-Immunologists are employed in HSCT
centers, but their expertise is only recognized in rare
diseases such as primary immune deficiencies and met-
abolic defects—a setting unattractive to the bread win-
ner and unrewarding to the ambitious. Very few of them
specialize on a full-time basis in transplantation, their
academic departments struggle for survival, and insur-
ance carriers question indications, whereas the demand
for HSCTs is overwhelming and keeps growing. This
discrepancy is hard to explain. Hematology-oncology
is based on a study of cell lineage, genetic variation, and
immune responses that are no different from the other
2 immunology-based specialties. Clinical experiences
with immune suppression and reconstitution overlap sig-
nificantly, and the advent of immunomodulators, mono-
clonal antibodies, and tyrosine kinase inhibitors now
brings these specialties closer. Significantly, fellowship
training in many U.S. accredited allergy-immunology
programs exceeds, at least in time, the HSCT exposure
that most hematology-oncology programs offer, and
the certification examination by the Board of Allergy
and Immunology has often included more questions on
HSCT than theequivalentexams by theBoards ofHema-
tology-Oncology [3].
Board certification in HSCT for physicians
recruited from immunology-based specialties will
increase the HSCT workforce, enlarge perspectives
and put (the whole) HSCT to the map of insurance
providers. More importantly, though, it will expand
the practice of HSCT to its full potential and prepare
the clinician for the times to come. Obviously, the au-
thors’ intention was to secure for HSCT its deserved
place while protecting the interests of the specialty of
hematology-oncology. It may be worth consid-
ering whether, in today’s political and financial
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ally served by keeping HSCT in the exclusive domain
of 1 specialty or by opening it up to the legitimate
practitioners of medical immunology. The very begin-
nings of HSCT—by immunologists—may serve as
precedent [4].REFERENCES
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Response to Letter from
Demetrios S. Theodoropoulos,
MD, DSc
We appreciate Dr. Theodoropoulos’ letter and
comments [1]. Dr. Theodoropoulos points out that
the rapid changes in medicine today in both personal-
ized molecular medicine and the emerging field of
regeneration medicine is creating a new landscape
that may alter our projections for the need for an
expanded hematopoietic stem cell transplantation
(HCT) workforce over the next decade. He is correct
that these numbers could ultimately be curbed some-
what from our projections that were made based on
the changing demographics of the aging population
of this country, the expanded indications, and as have
been documented with the recent publication by the
Healthcare Cost and Utilization Project, which dem-
onstrated that bone marrow transplant was associated
with the greatest percentage change and total hospital
stay during the years 2004 to 2007 [2]. However, based
on our current appreciation of personalized molecular
and regeneration medicine, we can at least be assured
that reduction is in transplant procedures will not
occur in the near future.
With regard to his suggestion that the field of HCT
be open to other disciplines, it should be noted that,
currently, FACT and NMDP accreditation recogni-
tion of HCT physicians are for individuals primarily
boarded as internists or pediatricians, with subspecialtytraining in hematology, medical oncology, and/or
immunology [3,4]. However, historically, nearly all
HCT providers have arisen from hematology/oncol-
ogy training programs. Recruiting physicians from
other specialty areas is an intriguing concept
for increasing the HCT workforce, and could be a po-
tential and welcome solution to some of the projected
workforce shortage.
HCT providers must have extensive knowledge of
inpatient medicine in addition to HCT-specific immu-
nology, treatment regimens, infectious complications,
cell collection by apheresis, and bone marrow harvest
and cell processing. HCT patients have a significant
need for inpatient services for management of pancyto-
penia, infectious complications, immunologic complica-
tions like graft-versus host disease (GVHD) and
comorbid diseases exacerbated by the transplant process.
Additionally, it is critical to understand the natural
history of the disorders for which HCT is utilized to
best balance the use of alternative therapies versus
transplantation. Consequently, because about 85% of
transplantsare done to treat malignancies, a firm ground-
ing in the care of oncologic diseases is essential, and the
reason that traditional HCT programs have arisen in
divisions of hematology and/or medical oncology.
One solution for the projected workforce shortage
is an ACGME accredited or nonaccredited fellowship.
Whether a 1-year HCT fellowship would successfully
provide the adequate background in management of
patients with hematologic malignancies or other trans-
plantable malignancies for physicians trained in allergy
and immunology or rheumatology fellowships, both of
which focus on outpatient care, is unclear. It might be
necessary to have a longer period of training for physi-
cians whose initial board certification does not address
competence in all of the oncologic and critical care
areas required for HCT practice. However, there
could be different areas of emphasis during a training
program with the recognition that the management
of the outpatient chronic medical conditions experi-
enced by the posttransplant patient may be better
served by individuals trained in the management of
outpatient immunology and rheumatologic disorders.
Board certification is to demonstrate a newly
trained physician has mastered a knowledge and skill
set to practice a given area of medicine. Recertification
should demonstrate that a physician practicing in the
area is maintaining an adequate knowledge and skill
set to continue to practice in that field. Bone and
marrow transplantation (BMT) fellowships do not
currently have a mandatory curriculum. The closest to
establishing a detailed skill set that should be
mastered by the HCT specialist is the FACT-
required procedural and knowledge skill set. However,
it should be noted that these guidelines do not distinctly
define a skill set needed for the management of complex
multiorgan illnesses in inpatients and outpatients. This
